Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24733204 | 0.92 | KDM4E (0.36) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL803502 | 0.76 | CYP2D6 (0.45) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL12030756 | 0.76 | KDM4E (0.40) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL15177092 | 0.75 | OPRM1 (0.40) | KDM4EMEN1ALDH1A1POLBMAPT | |
| SCHEMBL20047141 | 0.74 | ALDH1A1 (0.44) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL5357544 | 0.74 | KDM4E (0.42) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL25698197 | 0.74 | KDM4E (0.39) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL26890012 | 0.72 | CYP2D6 (0.33) | CYP2D6 | |
| SCHEMBL12590870 | 0.72 | CYP2D6 (0.42) | KDM4EMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL15461532 | 0.71 | KDM4E (0.37) | KDM4EMEN1ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2019-03-07 | — | — | US | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM2A | KDM4E 14/4885MEN1 1965/4885ALDH1A1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.